Antiplatelet Therapy: Targeting the TxA2 Pathway

摘要: The thromboxane (Tx) A2 pathway is a major contributor to the amplification of initial platelet activation process. TxA2 mediates its effect through prostanoid (TP) receptor that expressed not only in platelets, but also endothelial cells, macrophages, and monocytes, thus contributes development atherosclerotic lesions. therefore target treatment cardiovascular disease. Aspirin-the most widely used antiplatelet drug-is very effective at inhibiting platelet-derived synthesis. However, aspirin's effects can be overcome by several other soluble agonists such as isoprostanes, which are aspirin-insensitive ligands TP preferentially produced diabetes mellitus. Other drugs, with either inhibitory on Tx synthase or antagonist TP, have been developed hope providing better, more complete inhibition pathway.